{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:50Z","timestamp":1786986950332,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201800044C"],"award-info":[{"award-number":["HHSN272201800044C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014351","name":"CinnaGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cmi.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:16:11Z","timestamp":1650050171000},"page":"1263-1271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Safety and immunogenicity of SpikoGen\u00ae, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations"],"prefix":"10.1016","volume":"28","author":[{"given":"Payam","family":"Tabarsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Shahpari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Mardani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Sabzvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Roshanzamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Bayatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saghar","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.04.004_bib1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.cmi.2022.04.004_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2022.04.004_bib3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.04.004_bib4","doi-asserted-by":"crossref","first-page":"589833","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2022.04.004_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.04.004_bib6","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.04.004_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.04.004_bib8","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax\u2122 polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib9","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax\u2122, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib10","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax\u2122, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib11","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib12","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2015.07.051","article-title":"Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection","volume":"33","author":"Honda-Okubo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib13","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1016\/j.vaccine.2021.07.037","article-title":"A\u00a0M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization","volume":"39","author":"Sakala","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib14","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.vaccine.2014.06.057","article-title":"A\u00a0single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax\u2122) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection","volume":"32","author":"Honda-Okubo","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib15","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1016\/j.vaccine.2020.10.065","article-title":"Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity","volume":"38","author":"Eichinger","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib16","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2022.04.004_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted Middle East Respiratory Syndrome Coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2022.04.004_bib18","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/21645515.2018.1502517","article-title":"A\u00a0post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)","volume":"14","author":"Popmihajlov","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2022.04.004_bib19","series-title":"Development and licensure of vaccines to prevent COVID-19","author":"FDA","year":"2020"},{"key":"10.1016\/j.cmi.2022.04.004_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.04.004_bib21","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.04.004_bib22","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s40121-021-00521-8","article-title":"Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 total test in recently vaccinated individuals","volume":"10","author":"Jaganathan","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2022.04.004_bib23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.04.004_bib24","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1016\/j.vaccine.2021.10.075","article-title":"Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.04.004_bib25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2022.04.004_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/11316930-000000000-00000","article-title":"CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer","volume":"23","author":"Murad","year":"2009","journal-title":"BioDrugs"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:52Z","timestamp":1761118312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22002075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1198743X22002075"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.04.004","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of SpikoGen\u00ae, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}